Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (2923)	3/22/1998 12:39:00 PM
From: phbolton	Respond to of 7041

Questions (1) Why is Zona so far behind schedule? pslgroup.com "The approval of our U.S. VASOMAX(TM) patent, the VASOMAX(TM) IND submission and the selection of our Phase III development team are crucial events in our commercialization strategy," declared Joseph S. Podolski, president and CEO, Zonagen, Inc.. "Zonagen and its clinical partners have developed a very aggressive timeline for our U.S. clinical trials. We believe that we will be able to submit our VASOMAX(TM) NDA to the FDA in June of 1997." (2) if phase III is running so far behind schedule can they afford to complete it? (if it is still going on)